Dengue tetravalent vaccine, live - Biologic Drug Details

Summary for dengue tetravalent vaccine, live

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for dengue tetravalent vaccine, live

Recent Clinical Trials for dengue tetravalent vaccine, live

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Takeda	Phase 3
Takeda	Phase 2
National Institutes of Health (NIH)	Phase 1

See all dengue tetravalent vaccine, live clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for dengue tetravalent vaccine, live Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for dengue tetravalent vaccine, live Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Sanofi Pasteur Inc.	DENGVAXIA	dengue tetravalent vaccine, live	For Injection	125682	8,142,795	2029-07-09	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for dengue tetravalent vaccine, live Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source

International Patents for dengue tetravalent vaccine, live

Country	Patent Number	Estimated Expiration
Argentina	072796
Australia	2009267401
Brazil	PI0915813
Canada	2729758
China	102089002
Denmark	2310048
European Patent Office	2143440

Supplementary Protection Certificates for dengue tetravalent vaccine, live

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
19C1039	France		PRODUCT NAME: VIRUS CHIMERIQUES FIEVRE JAUNE/ DENGUE DE SEROTYPES 1, 2, 3 ET 4 (VIVANTS, ATTENUES); REGISTRATION NO/DATE: EU/1/18/1338 20181214

Market Dynamics and Financial Trajectory for Dengue Tetravalent Live Vaccines

Last updated: March 8, 2026

What are the key drivers influencing the dengue tetravalent live vaccine market?

The market for dengue tetravalent live vaccines is shaped by multiple factors:

• Disease prevalence: Dengue affects over 390 million annually, with approximately 100 million symptomatic cases and 22,000 deaths worldwide, predominantly in tropical and subtropical regions (WHO, 2022).

• Vaccine approvals: Two vaccines have received WHO prequalification—Dengvaxia (Sanofi) in 2016 and TAK-003 (Takeda) in 2021—stimulating market growth.

• Regulatory landscape: Variable approval statuses across countries influence market access, approval delays, and introduction strategies.

• Manufacturing capacity: Capacity expansions by Sanofi and Takeda have increased supply, reducing shortages and supporting broader distribution.

• Public health policies: Integration into immunization programs depends on country-specific policies, affecting uptake.

• Pricing and reimbursement: Governments and insurers influence access through pricing negotiations, subsidy programs, and reimbursement policies.

• Competitive landscape: Limited product portfolio constrains substitutive competition but encourages continued R&D efforts.

• Awareness and acceptance: Public perception, driven by safety profiles and efficacy data, impacts vaccination rates.

How do current market sizes and projections look?

The dengue vaccine market remains nascent but expanding:

Year	Estimated Market Size (USD billion)	Compound Annual Growth Rate (CAGR)	Notes
2022	0.2	—	Base year, limited regional adoption
2025	0.6	46%	Increasing approvals, expanding immunization programs
2030	1.5	36%	Market expected to triple; driven by emerging markets

Sources: MarketsandMarkets (2022), GlobalData (2023)

Projected CAGR exceeds 35%, reflecting growth potential, especially in Asia-Pacific and Latin America.

What are the financial considerations for vaccine producers?

• R&D investments: Development costs for live tetravalent vaccines approximate USD 300-500 million, including clinical trials. Regulatory approvals in multiple jurisdictions increase expenses.

• Manufacturing costs: High biotech production costs, including cold chain logistics, impact profit margins.

• Pricing strategies: Prices vary significantly; for example, Sanofi's Dengvaxia costs approximately USD 20-40 per dose in endemic countries, while TAK-003 is expected to target similar or lower price points.

• Market penetration: Adoption rates depend on vaccine efficacy, safety profile, and health policy endorsements.

• Revenue models: Revenue streams include government tenders, GAVI and UNICEF procurement contracts, and private sales.

• Cost recovery: Given substantial initial investments and variable revenues, companies require broad geographic coverage to achieve profitability.

What regulatory and geopolitical challenges influence market trajectory?

• Safety concerns: Post-approval reports linked Dengvaxia to increased risk of severe dengue in seronegative individuals, leading to revised guidelines and influencing market confidence.

• Approval delays: Suspensions, reevaluations, and regional regulatory processes delay market entry and expansion.

• Intellectual property: Patent protections for TAK-003 until 2032 influence competition and pricing.

• Geopolitical factors: Trade tensions and import restrictions influence supply chains.

How do regional variations affect market development?

Region	Key factors	Market potential
Southeast Asia	High dengue burden, aggressive vaccination programs	High, especially in Thailand, Indonesia
Latin America	Growing awareness, active public health campaigns	Moderate to high
Africa	Limited dengue endemicity but emerging concerns	Low, but potential growth in future
Middle East & North Africa	Increasing incidence, vaccination initiatives	Emerging opportunity

What is the financial outlook for stakeholders?

For vaccine manufacturers, long-term profitability hinges on:

• Achieving broad regional approvals
• Expanding manufacturing capacity
• Gaining market share through competitive pricing
• Securing long-term procurement agreements

For investors, key indicators include:

• R&D pipeline developments
• Regulatory approval timelines
• Strategic partnerships and licensing
• Market access negotiations

Key Takeaways

• The dengue tetravalent live vaccine market is growing rapidly, driven by disease burden and vaccine approvals.
• Revenue growth is projected to reach USD 1.5 billion by 2030, with a CAGR exceeding 35%.
• Manufacturing costs, safety concerns, and regional policy differences pose financial risks.
• Market expansion relies on regulatory approvals, public health policies, and acceptance.
• Competitive landscape remains constrained, but ongoing R&D efforts could introduce new entrants or improved formulations.

FAQs

1. What is the current market leader in dengue tetravalent vaccines?

Sanofi’s Dengvaxia remains the only WHO-approved dengue vaccine globally, with TAK-003 (Takeda) gaining approval in 2021. Market share favors Dengvaxia due to earlier approval and larger deployment.

2. How does safety profile impact market growth?

Safety concerns, especially in seronegative individuals, have led to positionings that limit Dengvaxia to seropositive populations. This restriction influences vaccination coverage and revenue potential.

3. Are there upcoming pipeline candidates?

Yes. Several biotech firms, including Butantan Institute and Instituto Butantan, are developing new dengue vaccines, some focusing on improving efficacy and safety profiles.

4. How do public health policies influence market dynamics?

Countries integrating dengue vaccination into national immunization programs face procurement and distribution challenges, affecting market size and growth rates.

5. What are the main barriers to market expansion in non-endemic regions?

Low disease prevalence reduces urgency and budget allocations for dengue vaccination, limiting market potential outside tropical zones.

---

References

[1] World Health Organization. (2022). Dengue and severe dengue. WHO Fact Sheet.
[2] MarketsandMarkets. (2022). Dengue Vaccine Market by Technology, Region, and End User.
[3] GlobalData. (2023). Asia-Pacific Vaccine Market Report.